Hinokiflavone

Hinokiflavone

SCHEMBL617272

O=c1cc(-c2ccc(Oc3c(O)cc4oc(-c5ccc(O)cc5)cc(=O)c4c3O)cc2)oc2cc(O)cc(O)c12

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.70
MAPT P10636 8/20 0.70
MEN1 O00255 7/20 0.70
FLT3 P36888 6/20 0.70
CYP1A1 P04798 5/20 0.70
CYP1B1 Q16678 5/20 0.70
MAOB P27338 5/20 0.70
ALDH1A1 P00352 5/20 0.70
CYP3A4 P08684 5/20 0.70
ABCB1 P08183 5/20 0.70
FTO Q9C0B1 5/20 0.70
XDH P47989 5/20 0.70
KDM4E B2RXH2 5/20 0.70
NPC1 O15118 4/20 0.70
TDP1 Q9NUW8 4/20 0.70
GABRP O00591 4/20 0.70
GABRD O14764 4/20 0.70
GABRA1 P14867 4/20 0.70
GABRB1 P18505 4/20 0.70
GABRG2 P18507 4/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hinokiflavone SCHEMBL30063752 1.00 KMT2A (0.70) KMT2AMAPTMEN1FLT3CYP1A1
SCHEMBL13485654 0.90 QPCT (0.80) KMT2AMAPTMEN1FLT3CYP1A1
SCHEMBL13672776 0.89 XDH (0.67) KMT2AMAPTMEN1FLT3CYP1A1
SCHEMBL13485651 0.88 MAPT (0.72) KMT2AMAPTMEN1FLT3CYP1A1
Hinokiflavone SCHEMBL4649967 0.88 MAPT (0.66) KMT2AMAPTMEN1FLT3CYP1A1
SCHEMBL30192733 0.87 CYP1B1 (0.80) KMT2AMAPTMEN1FLT3CYP1A1
SCHEMBL19715996 0.84 CYP3A4 (0.67) KMT2AMAPTMEN1FLT3CYP1A1
Apigenin SCHEMBL19428 0.84 KMT2A (1.00) KMT2AMAPTMEN1FLT3CYP1A1
Apigenin SCHEMBL29351464 0.84 KMT2A (1.00) KMT2AMAPTMEN1FLT3CYP1A1
Apigenin SCHEMBL5083245 0.84 KMT2A (1.00) KMT2AMAPTMEN1FLT3CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 588 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4698662-A2 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES AskBio Inc. (US) 2026-02-25 EP claimed
US-20260021167-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASES DELAWARE STATE UNIVERSITY (US) 2026-01-22 US claimed
US-20250339399-A1 SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) 2025-11-06 US claimed
US-20250262233-A1 COMPOSITION SpecNova LLC (US) 2025-08-21 US claimed
EP-2603098-B1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER FIRMENICH INCORPORATED (US) 2025-08-06 EP claimed
EP-4540406-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASES Kim, Yong Hwan (US) 2025-04-23 EP claimed
WO-2024220449-A9 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES AskBio Inc. (US) 2025-04-03 WO claimed
WO-2025024478-A1 COMPOSITIONS FOR THE MODULATION OF TASTE IXORA SCIENTIFIC INC. (US) 2025-01-30 WO claimed
WO-2024220449-A2 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) 2024-10-24 WO claimed
WO-2023244772-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASES KIM YONG HWAN (US) 2023-12-21 WO claimed
US-20020068757-A1 Biflavanoids and derivatives thereof as antiviral agents ADVANCED LIFE SCIENCES, INC. 2002-06-06 US claimed
US-6399654-B1 ADMINISTERING MIXTURE OF VIRICIDE AND BIOFLAVANOID ADVANCED LIFE SCIENCES, INC. 2002-06-04 US claimed
US-20010031735-A1 Flavonoide esters and their use notably in cosmetics COLETICA (FR) 2001-10-18 US claimed
CN-1290349-A Pharmaceutical grade ginkgo biloba PHARMAPRINT INC (US) 2001-04-04 CN claimed
EP-1027603-A2 PHARMACEUTICAL GRADE GINKGO BILOBA Pharmaprint, Inc. (US) 2000-08-16 EP claimed
WO-1999020291-A9 PHARMACEUTICAL GRADE GINKGO BILOBA PHARMAPRINT INC (US) 1999-08-12 WO claimed
WO-1999020291-A2 PHARMACEUTICAL GRADE GINKGO BILOBA PHARMAPRINT, INC. (US) 1999-04-29 WO claimed
WO-1998046238-A1 BIFLAVINOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS, ALONE OR IN COMBINATION WITH AT LEAST ONE KNOWN ANTIVIRAL AGENT MEDICHEM RESEARCH, INC. (US) 1998-10-22 WO claimed
EP-0833631-A1 BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS MEDICHEM RESEARCH, INC. (US) 1998-04-08 EP claimed
WO-1997000679-A1 BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS MEDICHEM RESEARCH, INC. (US) 1997-01-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021167-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASES SENP1, SUMO1, SUMO2 KMT2A 2862/4885MAPT 291/4885MEN1 2529/4885
US-20010031735-A1 Flavonoide esters and their use notably in cosmetics TYR, MITF, CYP2F1 KMT2A 1023/4885MAPT 2248/4885MEN1 674/4885
US-20250339399-A1 SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM S100A8, TP53, AQP1 KMT2A 4248/4885MAPT 259/4885MEN1 312/4885
US-20020068757-A1 Biflavanoids and derivatives thereof as antiviral agents HK2, GYS2, HK1 KMT2A 463/4885MAPT 3337/4885MEN1 836/4885
US-20250262233-A1 COMPOSITION GNG2, DSTN, PRSS12 KMT2A 4489/4885MAPT 2074/4885MEN1 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.